
Sign up to save your podcasts
Or


Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.
In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by: Adaptive Biotechnologies
The post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline with Blood Cancer United Podcast.
By Blood Cancer UnitedTesting for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.
In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by: Adaptive Biotechnologies
The post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline with Blood Cancer United Podcast.